316 related articles for article (PubMed ID: 15815947)
1. [Economic evaluation of acute migraine attack treatment with triptans in Spain].
Gracia-Naya M; Rejas Gutiérrez J; Latorre Jiménez A; González Garcia P
Neurologia; 2005 Apr; 20(3):121-32. PubMed ID: 15815947
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
[TBL] [Abstract][Full Text] [Related]
3. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.
Kelman L; Von Seggern RL
Am J Ther; 2006; 13(5):411-7. PubMed ID: 16988536
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine.
Chen LC; Ashcroft DM
Headache; 2008 Feb; 48(2):236-47. PubMed ID: 18179569
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis.
Thorlund K; Mills EJ; Wu P; Ramos E; Chatterjee A; Druyts E; Goadsby PJ
Cephalalgia; 2014 Apr; 34(4):258-67. PubMed ID: 24108308
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of oral triptan therapy in Sweden.
Ramsberg J; Henriksson M
Cephalalgia; 2007 Jan; 27(1):54-62. PubMed ID: 17212684
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation.
Mandema JW; Cox E; Alderman J
Cephalalgia; 2005 Sep; 25(9):715-25. PubMed ID: 16109054
[TBL] [Abstract][Full Text] [Related]
8. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.
Winner P; Linder SL; Lipton RB; Almas M; Parsons B; Pitman V
Headache; 2007 Apr; 47(4):511-8. PubMed ID: 17445100
[TBL] [Abstract][Full Text] [Related]
9. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
Headache; 2004; 44(7):661-8. PubMed ID: 15209687
[TBL] [Abstract][Full Text] [Related]
10. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy.
Gori S; Morelli N; Acuto G; Caiola F; Iudice A; Murri L
Minerva Med; 2006 Dec; 97(6):467-77. PubMed ID: 17213783
[TBL] [Abstract][Full Text] [Related]
11. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
McCormack PL; Foster RH
Pharmacoeconomics; 2005; 23(12):1283-98. PubMed ID: 16336021
[TBL] [Abstract][Full Text] [Related]
12. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.
Ferrari MD; Roon KI; Lipton RB; Goadsby PJ
Lancet; 2001 Nov; 358(9294):1668-75. PubMed ID: 11728541
[TBL] [Abstract][Full Text] [Related]
13. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
Ferrari MD; Goadsby PJ; Roon KI; Lipton RB
Cephalalgia; 2002 Oct; 22(8):633-58. PubMed ID: 12383060
[TBL] [Abstract][Full Text] [Related]
14. Rational migraine management: optimising treatment with the triptans.
Millson DS
Funct Neurol; 2000; 15 Suppl 3():182-91. PubMed ID: 11200789
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
16. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.
Dodick DW; Sandrini G; Williams P
CNS Drugs; 2007; 21(1):73-82. PubMed ID: 17190530
[TBL] [Abstract][Full Text] [Related]
17. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians.
Lipton RB; Cutrer FM; Goadsby PJ; Ferrari MD; Dodick DW; McCrory D; Liberman JN; Williams P
Curr Med Res Opin; 2005 Mar; 21(3):413-24. PubMed ID: 15811210
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials.
Belsey JD
Curr Med Res Opin; 2004 May; 20(5):659-69. PubMed ID: 15140331
[TBL] [Abstract][Full Text] [Related]
19. Triptan nonresponder studies: implications for clinical practice.
Dodick DW
Headache; 2005 Feb; 45(2):156-62. PubMed ID: 15705122
[TBL] [Abstract][Full Text] [Related]
20. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan.
Goldstein J; Tiseo PT; Albert KS; Li C; Sikes CR
Headache; 2006; 46(7):1142-50. PubMed ID: 16866718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
